# A Clinical Trial Comparing the Efficacy and Safety of Different Doses of BL0175 Injection in Treating Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer

> **NCT07658183** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Best-Link Bioscience, LLC** · enrollment: 120 (estimated)

## Conditions studied

- Breast Cancer (Locally Advanced or Metastatic)

## Interventions

- **DRUG:** BL0175

## Key facts

- **NCT ID:** NCT07658183
- **Lead sponsor:** Shanghai Best-Link Bioscience, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-20
- **Primary completion:** 2027-10-31
- **Final completion:** 2028-05-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07658183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07658183, "A Clinical Trial Comparing the Efficacy and Safety of Different Doses of BL0175 Injection in Treating Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07658183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*